Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 4Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

Cisplatin 27Gemcitabine 22toripalimab 19Radiotherapy, Intensity-Modulated 18Capecitabine 10Radiotherapy 8Magnetic Resonance Spectroscopy 8nimotuzumab 7camrelizumab 7Specimen Handling 7Immune Checkpoint Inhibitors 7spartalizumab 5Drug Therapy 5Docetaxel 5Nivolumab 4Biopsy 4sintilimab 3Surgical Procedures, Operative 3Radiosurgery 3Platinum 3Fluorouracil 3Endoscopy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tislelizumab 2pembrolizumab 2irinotecan sucrosofate 2envafolimab 2apatinib 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Carcinoma × Nivolumab × Clear all
NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06019130 2024-05-16

NPC-Nivo

German Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 2 Recruiting
57 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡